|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
|
US7232818B2
(en)
*
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8129346B2
(en)
|
2004-04-15 |
2012-03-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
WO2005111009A2
(en)
*
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
ES2510840T3
(es)
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
|
PL1830838T3
(pl)
|
2004-12-03 |
2013-07-31 |
Dana Farber Cancer Inst Inc |
Kompozycje i sposoby leczenia chorób neoplastycznych
|
|
WO2006063154A1
(en)
*
|
2004-12-07 |
2006-06-15 |
Proteolix, Inc. |
Composition for proteasome inhibition
|
|
US8716322B2
(en)
|
2005-11-09 |
2014-05-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
NZ597545A
(en)
|
2006-06-19 |
2013-07-26 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
US20090234150A1
(en)
*
|
2006-07-14 |
2009-09-17 |
Peter Carmeliet |
Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
|
|
US7642369B2
(en)
*
|
2006-09-12 |
2010-01-05 |
University Of Kentucky Research Foundation |
Epoxyketone-based immunoproteasome inhibitors
|
|
AU2016231532B2
(en)
*
|
2007-10-04 |
2018-05-10 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
AU2013203566B2
(en)
*
|
2007-10-04 |
2016-10-13 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
JP5734656B2
(ja)
*
|
2007-10-04 |
2015-06-17 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
|
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
EP2088205A1
(en)
|
2008-02-11 |
2009-08-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
AU2009246467A1
(en)
*
|
2008-05-12 |
2009-11-19 |
Nereus Pharmaceuticals, Inc. |
Salinosporamide derivatives as proteasome inhibitors
|
|
EA024364B1
(ru)
|
2008-10-21 |
2016-09-30 |
Оникс Терапьютикс, Инк. |
Способ лечения множественной миеломы
|
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
|
US20110009332A1
(en)
*
|
2009-07-09 |
2011-01-13 |
Southwest Research Institute |
Therapeutic Treatment Of Wounds
|
|
GB0914883D0
(en)
|
2009-08-26 |
2009-09-30 |
Univ Belfast |
Compound
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
CA2791651C
(en)
|
2010-03-01 |
2019-08-20 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
EP2555621A4
(en)
|
2010-04-07 |
2014-07-02 |
Onyx Therapeutics Inc |
CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
|
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
|
WO2013009923A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Creighton University |
Methods of promoting neuron growth
|
|
WO2013071163A2
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharamaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
|
EP2776043B1
(en)
|
2011-11-11 |
2018-02-21 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
|
US20160008382A1
(en)
|
2012-01-24 |
2016-01-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
WO2013123254A1
(en)
|
2012-02-15 |
2013-08-22 |
Cydex Pharmaceuticals, Inc. |
Manufacturing process for cyclodextrin derivatives
|
|
MX364393B
(es)
|
2012-05-08 |
2019-04-24 |
Onyx Therapeutics Inc |
Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
|
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
WO2014015016A1
(en)
|
2012-07-18 |
2014-01-23 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
US20150218212A1
(en)
*
|
2012-08-21 |
2015-08-06 |
Fluorinov Pharma Inc. |
Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
|
|
HK1213585A1
(zh)
|
2012-10-22 |
2016-07-08 |
Cydex Pharmaceuticals, Inc. |
烷基化环糊精组合物及其制备和使用方法
|
|
PL2968555T3
(pl)
|
2013-03-13 |
2020-11-16 |
Sanofi |
Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
|
|
EP2970225B1
(en)
|
2013-03-14 |
2018-08-15 |
Onyx Therapeutics, Inc. |
Dipeptide and tripeptide epoxy ketone protease inhibitors
|
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
|
WO2015009888A2
(en)
|
2013-07-19 |
2015-01-22 |
Onyx Therapeutics, Inc. |
Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
|
|
CN103360348B
(zh)
*
|
2013-07-25 |
2015-06-24 |
苏州鹏旭医药科技有限公司 |
一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
|
|
US20160215016A1
(en)
*
|
2013-09-06 |
2016-07-28 |
Sandoz Ag |
Synthesis of peptide epoxy ketones
|
|
CA2922210A1
(en)
*
|
2013-09-06 |
2015-03-12 |
Sandoz Ag |
Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
|
|
WO2015121769A1
(en)
|
2014-02-13 |
2015-08-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
|
|
CN103864889B
(zh)
*
|
2014-04-04 |
2017-01-11 |
重庆泰濠制药有限公司 |
环氧酮化合物、其制备方法及卡非佐米的制备方法
|
|
EP3183295B1
(en)
|
2014-08-22 |
2023-08-02 |
CyDex Pharmaceuticals, Inc. |
Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
US10329325B2
(en)
|
2014-09-24 |
2019-06-25 |
Biophore India Pharmaceuticals Pvt. Ltd |
Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
|
|
US20160115198A1
(en)
|
2014-10-27 |
2016-04-28 |
Apicore Us Llc |
Methods of making carfilzomib and intermediates thereof
|
|
CN104402973A
(zh)
*
|
2014-11-24 |
2015-03-11 |
重庆泰濠制药有限公司 |
一种卡非佐米无定型晶的制备方法
|
|
WO2016088031A1
(en)
|
2014-12-02 |
2016-06-09 |
Fresenius Kabi Oncology Limited |
A process for purification of carfilzomib
|
|
US10301353B2
(en)
|
2014-12-31 |
2019-05-28 |
Dr. Reddy's Laboratories Limited |
Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
|
|
WO2016170544A1
(en)
*
|
2015-04-22 |
2016-10-27 |
Msn Laboratories Private Limited |
Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide
|
|
US10364269B2
(en)
|
2015-05-21 |
2019-07-30 |
Laurus Labs Limited |
Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
|
|
CN106317188A
(zh)
*
|
2015-06-18 |
2017-01-11 |
重庆医药工业研究院有限责任公司 |
一种制备卡非佐米无定型物的方法
|
|
WO2017032487A1
(en)
|
2015-08-27 |
2017-03-02 |
Technische Universität München |
Proteasome inhibitor comprising a signal-emitting moiety
|
|
US20180362580A1
(en)
|
2015-12-11 |
2018-12-20 |
Mylan Laboratories Limited |
Crystalline and amorphous forms of carfilzomib
|
|
TWI636052B
(zh)
*
|
2015-12-31 |
2018-09-21 |
中化合成生技股份有限公司 |
無定形卡非佐米(i)的製備方法
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
TWI759301B
(zh)
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
|
EP3494126A1
(en)
|
2016-08-02 |
2019-06-12 |
Synthon BV |
Process for making carfilzomib
|
|
MY204928A
(en)
|
2016-08-05 |
2024-09-23 |
Amgen Inc |
Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
|
|
US11078231B2
(en)
|
2016-09-14 |
2021-08-03 |
Fresenius Kabi Oncology Ltd |
Process for purification of carfilzomib intermediate
|
|
EP3512602B1
(en)
|
2016-09-16 |
2024-03-27 |
HSF Pharmaceuticals |
Inhibitors of heat shock factors (hsf) and uses thereof
|
|
EP3330260A1
(en)
|
2016-12-01 |
2018-06-06 |
Enantia, S.L. |
Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
|
|
CN111108125A
(zh)
|
2017-09-14 |
2020-05-05 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
JP2021503441A
(ja)
|
2017-11-16 |
2021-02-12 |
アムジエン・インコーポレーテツド |
Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
|
|
KR20250050122A
(ko)
*
|
2017-12-08 |
2025-04-14 |
뉴로지엑스 엘엘씨 |
알츠하이머 질환에 대한 동기화된 세포 주기 유전자 발현 시험 및 관련된 치료 방법
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
US10689416B2
(en)
*
|
2017-12-30 |
2020-06-23 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
EP3548504B1
(en)
*
|
2017-12-30 |
2021-07-21 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
CN113286586A
(zh)
*
|
2018-06-22 |
2021-08-20 |
Ucl商业有限公司 |
新化合物
|
|
US20240092831A1
(en)
*
|
2019-10-11 |
2024-03-21 |
Mayo Foundation For Medical Education And Research |
Proteasome Inhibitors
|
|
WO2021216670A1
(en)
*
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
KR20250008774A
(ko)
|
2022-05-11 |
2025-01-15 |
셀진 코포레이션 |
T 세포 요법 및 그의 생산과 관련된 방법 및 용도
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2024069240A2
(en)
|
2022-09-29 |
2024-04-04 |
Takeda Pharmaceutical Company Limited |
Cd38-binding fusion protein combination therapy
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
CN116768972A
(zh)
*
|
2023-06-25 |
2023-09-19 |
重庆药友制药有限责任公司 |
一种卡非佐米中间体的制备方法
|
|
WO2025035020A2
(en)
|
2023-08-09 |
2025-02-13 |
Amgen Inc. |
Methods of using carfilzomib
|
|
EP4685151A1
(en)
|
2024-07-24 |
2026-01-28 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Proteasome inhibitor
|